Loading…
Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion
Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and...
Saved in:
Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2014-12, Vol.54 (12), p.3080-3087 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13 |
---|---|
cites | cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13 |
container_end_page | 3087 |
container_issue | 12 |
container_start_page | 3080 |
container_title | Transfusion (Philadelphia, Pa.) |
container_volume | 54 |
creator | Rioux-Massé, Benjamin Cohn, Claudia Lindgren, Bruce Pulkrabek, Shelly McCullough, Jeffrey |
description | Background
Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion.
Study Design and Methods
We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves.
Results
Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other.
Conclusions
The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching. |
doi_str_mv | 10.1111/trf.12739 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1637567714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1637567714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</originalsourceid><addsrcrecordid>eNp1kF9rFDEUxUNR2rX2oV-gDIigD9Pmz2SyeVyq24qLFmnpY8gkd-jU2cmaZND103u3u11BMA8Jl_zOufceQk4ZPWd4LnJszxlXQh-QCZNClVxr-YJMKK1YyZjgR-RVSo-UUq4pOyRHvNKsFlM-IXCXu777bXMXhiK0hYshpXJps3sAX4RYXC9m-3LV2ww95FS0-LNCEQxYRGijdTnEdZHDHipytENqx4TOr8nL1vYJTnbvMbmbf7y9vC4XX68-Xc4WpZNS6VKD9tDoae3BqqrSlZQt4CU8957Vjk-VbbRTQoBsWa197W1DqVSWNZx6Jo7Ju63vKoYfI6Rsll1y0Pd2gDAmg0srWSvFKkTf_IM-hjEOON2GklQJrjbU-y31lAsualaxW9q4NoyaTfYGszdP2SN7tnMcmyX4PfkcNgJvd4BNzvYY2uC69JfTdIqdBXIXW-5n18P6_x3N7bf5c-tyq-hShl97hY3fTa1wZXP_5crMP1Q3N_wzN_fiDyGhqlM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1635073274</pqid></control><display><type>article</type><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</creator><creatorcontrib>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</creatorcontrib><description>Background
Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion.
Study Design and Methods
We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves.
Results
Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other.
Conclusions
The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.12739</identifier><identifier>PMID: 24916382</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Hoboken, NJ: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Platelets ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Child ; Female ; Histocompatibility Testing ; Humans ; Male ; Medical sciences ; Middle Aged ; Platelet Transfusion ; Retrospective Studies ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Transfusion (Philadelphia, Pa.), 2014-12, Vol.54 (12), p.3080-3087</ispartof><rights>2014 AABB</rights><rights>2015 INIST-CNRS</rights><rights>2014 AABB.</rights><rights>Copyright © 2014 AABB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</citedby><cites>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=29086353$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24916382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rioux-Massé, Benjamin</creatorcontrib><creatorcontrib>Cohn, Claudia</creatorcontrib><creatorcontrib>Lindgren, Bruce</creatorcontrib><creatorcontrib>Pulkrabek, Shelly</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Background
Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion.
Study Design and Methods
We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves.
Results
Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other.
Conclusions
The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Child</subject><subject>Female</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Platelet Transfusion</subject><subject>Retrospective Studies</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kF9rFDEUxUNR2rX2oV-gDIigD9Pmz2SyeVyq24qLFmnpY8gkd-jU2cmaZND103u3u11BMA8Jl_zOufceQk4ZPWd4LnJszxlXQh-QCZNClVxr-YJMKK1YyZjgR-RVSo-UUq4pOyRHvNKsFlM-IXCXu777bXMXhiK0hYshpXJps3sAX4RYXC9m-3LV2ww95FS0-LNCEQxYRGijdTnEdZHDHipytENqx4TOr8nL1vYJTnbvMbmbf7y9vC4XX68-Xc4WpZNS6VKD9tDoae3BqqrSlZQt4CU8957Vjk-VbbRTQoBsWa197W1DqVSWNZx6Jo7Ju63vKoYfI6Rsll1y0Pd2gDAmg0srWSvFKkTf_IM-hjEOON2GklQJrjbU-y31lAsualaxW9q4NoyaTfYGszdP2SN7tnMcmyX4PfkcNgJvd4BNzvYY2uC69JfTdIqdBXIXW-5n18P6_x3N7bf5c-tyq-hShl97hY3fTa1wZXP_5crMP1Q3N_wzN_fiDyGhqlM</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Rioux-Massé, Benjamin</creator><creator>Cohn, Claudia</creator><creator>Lindgren, Bruce</creator><creator>Pulkrabek, Shelly</creator><creator>McCullough, Jeffrey</creator><general>Blackwell Publishing Ltd</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><author>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Child</topic><topic>Female</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Platelet Transfusion</topic><topic>Retrospective Studies</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rioux-Massé, Benjamin</creatorcontrib><creatorcontrib>Cohn, Claudia</creatorcontrib><creatorcontrib>Lindgren, Bruce</creatorcontrib><creatorcontrib>Pulkrabek, Shelly</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rioux-Massé, Benjamin</au><au>Cohn, Claudia</au><au>Lindgren, Bruce</au><au>Pulkrabek, Shelly</au><au>McCullough, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2014-12</date><risdate>2014</risdate><volume>54</volume><issue>12</issue><spage>3080</spage><epage>3087</epage><pages>3080-3087</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>Background
Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion.
Study Design and Methods
We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves.
Results
Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other.
Conclusions
The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</abstract><cop>Hoboken, NJ</cop><pub>Blackwell Publishing Ltd</pub><pmid>24916382</pmid><doi>10.1111/trf.12739</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1132 |
ispartof | Transfusion (Philadelphia, Pa.), 2014-12, Vol.54 (12), p.3080-3087 |
issn | 0041-1132 1537-2995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1637567714 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Platelets Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Child Female Histocompatibility Testing Humans Male Medical sciences Middle Aged Platelet Transfusion Retrospective Studies Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
title | Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T12%3A52%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utilization%20of%20cross-matched%20or%20HLA-matched%20platelets%20for%20patients%20refractory%20to%20platelet%20transfusion&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Rioux-Mass%C3%A9,%20Benjamin&rft.date=2014-12&rft.volume=54&rft.issue=12&rft.spage=3080&rft.epage=3087&rft.pages=3080-3087&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.12739&rft_dat=%3Cproquest_cross%3E1637567714%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1635073274&rft_id=info:pmid/24916382&rfr_iscdi=true |